

poly(I:C) (54) imiquimod (55) and Freund's incomplete adjuvant (56). Immune adjuvants can increase the immunostimulatory effect of the vaccine (57,58,59).

V. CONCLUDING REMARKS

Elements of clinical trial design include timing of doses, concurrent dosing, sequential dosing, run-in periods, treatments in the order A then B (and vice versa), and decision trees. The present chapter concerns treatments in the order A and B (and vice versa), as it applies to neoadjuvant therapy, surgery, and adjuvant therapy.

⁵⁴ Verdeil G, Marquardt K, Surh CD, Sherman LA. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. *Proc Natl Acad Sci USA*. 2008;105:16683–16688.

⁵⁵ van den Boorn JG, Konijnenberg D, Tjin EP, et al. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. *PLoS One*. 2010;5:e10626.

⁵⁶ Miller LH, Saul A, Mahanty S. Revisiting Freund's incomplete adjuvant for vaccines in the developing world. *Trends Parasitol*. 2005;21:412–414.

⁵⁷ Jahrsdörfer B, Weiner GJ. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. *Curr Opin Investig Drugs*. 2003;4:686–690.

⁵⁸ Aoki N, Xing Z. Use of cytokines in infection. *Expert Opin Emerg Drugs*. 2004;9:223–236.

⁵⁹ Ishii KJ, Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. *J Clin Immunol*. 2007;27:363–371.